China Resources Pharmaceutical Group Dividend
Dividend criteria checks 2/6
China Resources Pharmaceutical Group is a dividend paying company with a current yield of 2.99% that is well covered by earnings. Next payment date is on 19th July, 2024 with an ex-dividend date of 4th June, 2024.
Key information
3.0%
Dividend yield
25%
Payout ratio
| Industry average yield | 3.4% |
| Next dividend pay date | 19 Jul 24 |
| Ex dividend date | 04 Jun 24 |
| Dividend per share | n/a |
| Earnings per share | HK$0.61 |
| Dividend yield forecast in 3Y | 3.5% |
Recent dividend updates
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28Recent updates
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, 3320 has been paying a dividend for less than 10 years.
Growing Dividend: 3320's dividend payments have increased, but the company has only paid a dividend for 7 years.
Dividend Yield vs Market
| China Resources Pharmaceutical Group Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (3320) | 3.0% |
| Market Bottom 25% (HK) | 3.2% |
| Market Top 25% (HK) | 7.8% |
| Industry Average (Pharmaceuticals) | 3.4% |
| Analyst forecast in 3 Years (3320) | 3.5% |
Notable Dividend: 3320's dividend (2.99%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (3.22%).
High Dividend: 3320's dividend (2.99%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.84%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (25.1%), 3320's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (7.7%), 3320's dividend payments are thoroughly covered by cash flows.